[{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s Aflibercept Injection (EyleaTM) for Intravitreal use Receives DCGI Approval for Diabetic Macular Edema Indication","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aflibercept 8 mg First to Achieve Extended Injection Intervals of 16 Weeks in Up to 89% of Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eylea\u00ae Approved in Japan for Treatment of Preterm Infants With Retinopathy of Prematurity","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Receives Positive CHMP Opinion For Eylea\u2122 In The EU For Treatment Of Preterm Infants With Retinopathy Of Prematurity","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Xbrane Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stada and Xbrane Obtain British Approval for Ximluci\u00ae (ranibizumab) Biosimilar Referencing Lucentis\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"STADA Arzneimittel"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Aflibercept 8 mg for Regulatory Approval in Two Major Retinal Eye Diseases in The EU","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Aflibercept 8 Mg for Marketing Authorization in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaliq Announces FDA Approval of Vevye (Cyclosporine Ophthalmic Solution) 0.1% for the Treatment of the Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Novaliq"},{"orgOrder":0,"company":"Novaliq","sponsor":"SENJU PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Senju Pharmaceutical and Novaliq Enter into License Agreement for NOV03 (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of Dry Eye Disease in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Novaliq"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aflibercept 8 Mg in Diabetic Macular Edema First to Achieve Sustained Vision Gains with up to 83% of Patients Extended to 16-24 Weeks at Two Years","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Novaliq","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE\u00ae (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Novaliq"},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Novaliq\u2019s Marketing Authorization Application for CyclASol\u00ae (ciclosporin ophthalmic solution) 0.1% for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Novaliq"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Application for Regulatory Approval of Aflibercept 8 mg Accepted in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Eylea\u2122 8 mg Approved in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Bayer AG"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Eylea (aflibercept) is a PGF & VEGF-A inhibitor, It is being evaluated in phase 3 clinical trials for the treatment of neovascular (wet) age-related macular degeneration.
Eylea (aflibercept) is a PGF & VEGF-A inhibitor, It is now approved in Japan for the treatment of neovascular (wet) age-related macular degeneration & diabetic macular edema.
CyclASol (cyclosporine) solubilized in a novel water-free excipient, perfluorobutylpentane, it is specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients.
Through acquisition, Harrow gains U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.
Vevye (cyclosporine ophthalmic solution) is solubilized in a novel and was designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy.
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.